title: Efficacy of the BioXtra dry mouth care system in the treatment of radiotherapy-induced xerostomia.
abstract: BACKGROUND
  Xerostomia is a common complication of radiotherapy for head and neck cancer. Symptomatic treatment consists of stringent oral hygiene to prevent oral infections and saliva substitutes to increase comfort. The aim of the study was to evaluate the clinical effectiveness of the BioXtra (BX) dry mouth care system.
  
  
  METHODS
  A xerostomia questionnaire consisting of 3 parts (xerostomia symptom score, quality of life (QoL) survey and visual analogue scale (VAS)) was completed by 34 patients suffering from radiation-induced xerostomia, before and after 4 weeks of treatment with the BioXtra moisturizing gel, toothpaste and mouthwash.
  
  
  RESULTS
  The BioXtra products significantly diminished the most common symptoms of xerostomia. Mean VAS score at the start of treatment was 59.8. After treatment, this decreased to 36.4 (p < 0.001). Twenty-six patients (77%) responded to treatment, 11 of these patients (32%) reported a major improvement. Quality of life significantly improved under treatment: mean QoL score at the start was 59.4; this increased to 70.5 (p < 0.001). None of the 34 patients reported any adverse effects and all but 1 patient found the BX dry mouth care system easy to use.
  
  
  CONCLUSIONS
  The results of this study suggest that the BioXtra dry mouth care system is effective in reducing the symptoms of radiation-induced xerostomia and improving the quality of life of xerostomia patients, even if a proportion of the benefit is due to a placebo effect. However, further research is necessary to evaluate the efficacy of BioXtra on oral health.
authors.affiliation: Department of Radiation Oncology, Leuvens Kanker Instituut, University Hospital Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium. piet.dirix@uz.kuleuven.ac.be
authors.forename: Piet
authors.initials: P
authors.lastname: Dirix
authors.forename: Sandra
authors.initials: S
authors.lastname: Nuyts
authors.forename: Vincent
authors.initials: V
authors.lastname: Vander Poorten
authors.forename: Pierre
authors.initials: P
authors.lastname: Delaere
authors.forename: Walter
authors.initials: W
authors.lastname: Van den Bogaert
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D045424:Complex Mixtures; D005260:Female; D006258:Head and Neck Neoplasms; D006306:Health Surveys; D006801:Humans; D007781:Lactoferrin; D007784:Lactoperoxidase; D008297:Male; D008875:Middle Aged; D009113:Muramidase; D010147:Pain Measurement; D011506:Proteins; D011581:Psychological Tests; D011594:Psychometrics; D011788:Quality of Life; D011832:Radiation Injuries / Q000209:etiology*; D018787:Radiation Oncology; D011878:Radiotherapy / Q000009:adverse effects*; D011879:Radiotherapy Dosage; D012307:Risk Factors; D012463:Saliva / Q000528:radiation effects; D012472:Salivation / Q000528:radiation effects; D011795:Surveys and Questionnaires; D014987:Xerostomia / Q000209:etiology*; D014993:Xylitol
chemical_list: C460819:BioXtra; D045424:Complex Mixtures; D011506:Proteins; D007784:Lactoperoxidase; D009113:Muramidase; D007781:Lactoferrin; D014993:Xylitol